Cellectis S.A. Sponsored ADR CLLS 深 沪
已收盘 05-22 16:00:00 美东时间
3.50
-0.020
-0.57%
华盛通- 最 高3.6781
- 今 开3.61
- 成交量 1.35万股
- 最 低 3.50
- 昨 收 3.52
- 总市值 3.52亿
- 52周最高 5.4796
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 1.3271
- 委 比 95.68%
- 总股本 1.01亿
- 历史最高 50.00
- 量 比 0.38
- 振 幅 5.06%
- 历史最低 0.9628
- 每 手 1
- 风险率 1.01%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cellectis To Present Phase 1 CAR-T Data For Lasme-cel And Eti-cel At EHA 2026, Highlighting Early Safety, Response Signals And Ongoing Pivotal Programs
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced upcoming presentations on the
05-12 21:34
Cellectis Q1 Adj. EPS $(0.16) Beats $(0.27) Estimate, Sales $7.548M Miss $12.267M Estimate
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.27) by 40.74 percent. This is a 5.88 percent increase over losses of $(0.17) per share from the same
05-12 04:32
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
Cellectis Presents New Research On TALE-Based Epigenetic Editing Approach At ASGCT Annual Meeting
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today presents new research on a TALE-based
04-28 04:33
美股大行评级 | 小摩上调Bloom Energy目标价从166美元升至231美元；目标价28美元！大摩、高盛等多家机构首予Janus Living(JAN)超配评级
今日重点评级关注：Ascendiant Capital：维持Banzai International"买入"评级，目标价从23美元升至24美元；Ascendiant Capital：维持Synergy CHC Corp."买入"评级，目标价从5美元升至5.5美元
04-15 11:31
Citizens Reiterates Market Outperform on Cellectis, Maintains $8 Price Target
Citizens analyst Silvan Turkcan reiterates Cellectis (NASDAQ:CLLS) with a Market Outperform and maintains $8 price target.
04-14 20:40
Allogene Therapeutics Hits 52-Week High - Here's Why
Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to delay relapse in lymphoma patients.
04-14 00:59
Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt rose on news of being acquired by Somnigroup.
04-13 22:29
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 76.7% to $0.18 du...
04-13 20:05
Earnings Scheduled For March 19, 2026
Companies Reporting Before The Bell • Neuraxis (AMEX:NRXS) is projected to repo...
03-19 19:11
